Rubicon Research (RUBICON.NS) Stock Price

Rubicon Research Price

CLOSED
1,535.40
​
Market closed

Revenue has compounded at 63.9% per year over the past 3 years to 17.31 B INR. Rubicon Research's net margin stands at 14.3%, up from -4.3% several years earlier. Analysts set a median price target of 874.65 INR, implying 43.0% below the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Rubicon Research stock price

Access this data via the Eulerpool API

Rubicon Research business model & stock analysis

Rubicon Research Ltd. engages in the manufacturing and export of formulations spanning a diverse range of dosage forms and therapeutic areas. The company is headquartered in Thane, Maharashtra and currently employs 1,141 full-time employees. The company went IPO on 2025-10-16. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.

Frequently asked questions about Rubicon Research

Analysts currently set an average price target of 874.65 INR for the Rubicon Research stock (median: 874.65 INR), implying -43.0 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Rubicon Research stock: 7 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Rubicon Research share trades at 14.17 EUR (1,535.40 INR).

The revenue of Rubicon Research is 17.31 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Rubicon Research is 2.47 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Rubicon Research is currently 102.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Rubicon Research stock.

The price-to-sales ratio (P/S) of Rubicon Research is currently 14.61. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Rubicon Research stock.

The Eulerpool Quality Score for Rubicon Research is 4/10.

The ISIN of Rubicon Research is INE506V01022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Rubicon Research is RUBICON.NS. The ticker symbol is used to trade Rubicon Research shares on the stock exchange.

Fair ValueTerminal
1,335.80 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue per Employee
15.17 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Oct 16, 2025
ISIN
INE506V01022
Cusip
Y7361W142
Market capitalization
252.96 B INRMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
71.41
P/Ee 2028
53.22
P/Se
10.85
EV/EBIT
70.92
P/B Ratio
19.63
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
17.23 %
Last updated Oct 10, 2026, 5:56 PM

Rubicon Research Peer Group